Rivaroxaban inhibits Factor Xa, whereas VKAs inhibit the glycosylation of multiple vitamin K-dependent coagulation proteins. TF: Tissue factor; VKA: Vitamin K antagonist.
rivaroxaban, 0.38 [95% confidence interval {CI}, 0.24 to 0.60]; hazard ratio for 90-mg abelacimab vs. rivaroxaban, 0.31 [95% CI, 0.19 to 0.51]; P<0.001 for both comparisons). The incidence and ...
The results of the Regulation of Coagulation in Major Orthopedic Surgery Reducing the Risk of DVT and PE (RECORD) studies showed that rivaroxaban is more effective than enoxaparin in the ...
In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback